Get started
Moderna, Inc.Moderna, Inc.Moderna, Inc.

Moderna, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

MRNA chart


Full chart

Key facts today


Several firms have cut their price targets for Moderna (MRNA), with Barclays at $40, Morgan Stanley at $31, and UBS at $70, while the average target is $45.43.
In Q1 2025, Moderna's Spikevax sales reached $84 million, with $2 million from its RSV vaccine. Operating expenses fell to $1.16 billion, a 19% decrease from Q1 2024.
Analyze the impactAnalyze the impact

MRNA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.01 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−9.28 USD
Net income (FY)
‪−3.56 B‬ USD
Revenue (FY)
‪3.24 B‬ USD
Shares float
‪341.66 M‬
Beta (1Y)
1.06

Employees


Employees (FY)
‪5.8 K‬
Change (1Y)
+200 +3.57%
Revenue / Employee (1Y)
‪557.93 K‬ USD
Net income / Employee (1Y)
‪−613.97 K‬ USD

About Moderna, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Stéphane Bancel
Website
modernatx.com
Headquarters
Cambridge
Founded
2010
FIGI
BBG003PHHZT1
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRNA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where MRNA is featured.

See all sparks 


Check out other big names from the same industry as MRNA.

Frequently Asked Questions


The current price of MRNA is 27.50 USD — it has decreased by −5.29% in the past 24 hours. Watch Moderna, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moderna, Inc. stocks are traded under the ticker MRNA.
MRNA stock has risen by 1.39% compared to the previous week, the month change is a −5.82% fall, over the last year Moderna, Inc. has showed a −76.06% decrease.
We've gathered analysts' opinions on Moderna, Inc. future price: according to them, MRNA price has a max estimate of 212.00 USD and a min estimate of 20.00 USD. Watch MRNA chart and read a more detailed Moderna, Inc. stock forecast: see what analysts think of Moderna, Inc. and suggest that you do with its stocks.
MRNA reached its all-time high on Aug 10, 2021 with the price of 497.49 USD, and its all-time low was 11.54 USD and was reached on Aug 7, 2019. View more price dynamics on MRNA chart.
See other stocks reaching their highest and lowest prices.
MRNA stock is 3.94% volatile and has beta coefficient of 1.06. Track Moderna, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moderna, Inc. there?
Today Moderna, Inc. has the market capitalization of ‪10.43 B‬, it has increased by 6.68% over the last week.
Yes, you can track Moderna, Inc. financials in yearly and quarterly reports right on TradingView.
Moderna, Inc. is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNA earnings for the last quarter are −2.52 USD per share, whereas the estimation was −3.12 USD resulting in a 19.13% surprise. The estimated earnings for the next quarter are −2.98 USD per share. See more details about Moderna, Inc. earnings.
Moderna, Inc. revenue for the last quarter amounts to ‪108.00 M‬ USD, despite the estimated figure of ‪106.18 M‬ USD. In the next quarter, revenue is expected to reach ‪112.46 M‬ USD.
MRNA net income for the last quarter is ‪−1.12 B‬ USD, while the quarter before that showed ‪13.00 M‬ USD of net income which accounts for ‪−8.72 K‬% change. Track more Moderna, Inc. financial stats to get the full picture.
No, MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 2, 2025, the company has ‪5.8 K‬ employees. See our rating of the largest employees — is Moderna, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Moderna, Inc. EBITDA is ‪−3.76 B‬ USD, and current EBITDA margin is −116.07%. See more stats in Moderna, Inc. financial statements.
Like other stocks, MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moderna, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moderna, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moderna, Inc. stock shows the sell signal. See more of Moderna, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.